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Abstract
Loss of function mutations in the receptor tyrosine kinase TrkB pathway resulted in hyperphagia and morbid obesity in
human and rodents. Conversely, peripheral or central stimulation of TrkB by its natural ligands BDNF or NT4 reduced body
weight and food intake in mice, supporting the idea that TrkB is a key anorexigenic signal downstream of the melanocortin-
4 receptor (Mc4r) system. Here we show that in non-human primates TrkB agonists were anorexigenic when applied
centrally, but surprisingly orexigenic, leading to gain in appetite, body weight, fat deposits and serum leptin levels, when
given peripherally. The orexigenic and pro-obesity effects of peripherally administered TrkB agonists appear to be dose
dependent, not associated with fluid retention nor with evidence of receptor down regulation. Our findings revealed that
TrkB signaling exerts dual control on energy homeostasis in the primates that could be targeted for the treatment of either
wasting disorders or obesity.
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Introduction
Brain-derived neurotrophic factor (BDNF) and neurotrophin-4
(NT4) are two naturally occurring ligands for the receptor tyrosine
kinase trkB [1]. Originally viewed as trophic factors for neuronal
survival and neurite outgrowth during embryonic development,
these factors can actually exert a wide range of biological functions
in the adult, such as long term potentiation and synaptic plasticity.
The mRNA of BDNF is normally expressed in the ventromedial
hypothalamus (VMH) [2,3,4,5]. The VMH expression of BDNF
mRNA is reduced under several conditions where the appetite is
increased, such as food deprivation, melanocortin antagonism (as
in A
y lethal yellow mice) and genetic ablation of melanocortin 4
receptor (Mc4r) [3].
The loss-of-function mutations of BDNF or trkB loci in mice led
to a syndrome of hyperphagia and obesity. These include mice
heterozygous with a BDNF deficient allele [2,4], mice with
postnatal brain-specific BDNF deletion [5], as well as mice with a
hypomorphic allele of trkB [3]. Remarkably a de novo trkB
mutation was identified in a mentally retarded, morbidly obese
child [6]. The kinase activity of this mutant human trkB allele is
greatly diminished. In addition, a human case of hyperphagia and
obesity was found to harbor a chromosomal translocation affecting
BDNF expression [7]. Furthermore, both central and peripheral
administration of various TrkB agonists suppressed food intake
and body weight in several mouse models of obesity [2,3,8,9].
These findings together support the notion that trkB activation by
BDNF expressed in the brain is essential for appetite regulation
and energy homeostasis.
To investigate the feasibility of trkB agonism as a therapeutic
approach for human obesity, we conducted a series of experiments
using NT4, BDNF and TrkB agonistic antibody in several species
of non-human primates. Both NT4 and BDNF, when delivered into
thebraindirectly,suppressedfoodconsumptionintheleanmonkeys.
Contrary to our expectation, however, NT4 and TrkB agonistic
antibody significantly increased food intake, body weight, fat mass
and circulating leptin levels in the lean monkeys and even in the
obese baboons. Further analysis suggested a novel, peripherally
accessible, orexigenic TrkB system, which when activated can
counter-balance the central, anorexigenic TrkB system.
Results
Administration of TrkB Agonists Result in Hypophagia
and Weight Loss in Mice
Since NT4 has very similar agonist profile as BDNF [10,11,12],
we use these two factors separately and interchangeably as the
naturally occurring, TrkB agonist agents. Daily intravenous (IV)
treatment of diet induced obesity (DIO) mouse model with 0.6, 2
or 4 mg/kg of NT4 led to a dose dependent reduction in food
intake (Fig. 1a) and body weight (Fig. 1b). Weight reduction was
also observed at Day 11 following weekly IV injections of 2mg/kg
of BDNF, 2mg/kg of NT4 (Fig. 1c) or a single IV injection of
3mg/kg of a TrkB selective agonist antibody (Fig. 1d; Tsao et al,
2007; for more details on the generation and characterization of
the TrkB agonist antibody see also Supplemental Methods S1,
Supplemental Figs S1–S2 and Supplemental Table S1). Daily
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mice with 20 mg/kg of NT4 (n=8 per group) for 30 days also led
to a sustained 50–80% decrease in daily food intake (Fig. 1e), and
a linearly time-dependent, 40% decrease in body weight (Fig. 1f),
confirming that activation of TrkB alone causes anorexia and
weight loss in rodents independent of the leptin signal [9]. No
tolerance, desensitization, adaptation or resistance to the extended
exposure to high dose of NT4 was evident under these treatment
conditions.
Central Administration of TrkB Agonists Suppress Food
Intake in Monkeys
Similar to the findings with central administration of TrkB
agonists in mice [2,8,9], an anorexigenic effect was observed in
adult Rhesus monkeys that received intracerebroventricular (ICV)
injection of BDNF or NT4 (30–300 mg) compared to the vehicle
injection (Figs 2a, 2b). The reduction in food intake after ICV
injections in the Rhesus was fully reversible within 3–4 days and
was not accompanied by signs of inflammation, such as fever or
Figure 1. Treatment with TrkB agonists reduces food intake and weight in mice. a, Daily IV injection of 0.6, 2 or 4 mg/kg of NT4 (n=6 per
group) resulted in dose dependent reduction in average daily food intake over 5 days in adult male DIO mice (One way ANOVA, P=0.0098, F=4.967
with Dunnett’s posttest, P,0.01 for 4 mg/kg group compared to the vehicle group, while no statistically significant effects were observed at 0.6 or
2 mg/kg). b, Daily IV injection of 0.6, 2 or 4 mg/kg of NT4 (n=6 per group) resulted in dose dependent reduction in body weight in adult male DIO
mice (Two way ANOVA, P,0.0001 with Bonferroni’s posttests, data are presented as % change relative to baseline body weight). c, Weekly IV
injection of 2 mg/kg BDNF (n=7) or NT4 (n=7) led to significant weight loss compared to the vehicle treatment (n=8) in adult male DIO mice at
10 days after the first dose (One way ANOVA, P=0.002, F=9.08 with Dunnett’s posttest). d, Single IV injection of 3 mg/kg TrkB agonist monoclonal
antibody (n=7) significantly reduced body weight relative to control IgG treatment (n=7) in adult male DIO mice 10 days after dosing (Student’s t
test, 2 tailed, P=0.04). e–f, Daily treatment of Leptin receptor-deficient, 12 week old female db/db mice for 30 days with IV-delivered 20 mg/kg of
NT4 (n=7) decreased daily food intake by 50–80% (e), and body weight by 40% (f) relative to the vehicle treated mice (n=8).
doi:10.1371/journal.pone.0001900.g001
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TrkB activation in the central nervous system mediates a robust
anorexigenic signal in both mice and non-human primates.
Peripheral Administration of TrkB Agonists Lead to
Hyperphagia and Weight Gain in Monkeys
Unlike the central delivery of TrkB agonists, daily SC
administration of NT4 at 2 mg/kg in lean adult Rhesus monkeys
over 21 days led to 10–15% body weight gain relative to the
vehicle group (n=1 male and 2 females per group) without
significantly affecting daily food intake (Fig. 2c and data not
shown). Moreover, lean adult female Cynomolgus monkeys that
received daily SC (4 hour post-dosing serum NT4 levels at 600–
1200 ng/mL) or IV (peak serum NT4 levels at 5–12 mg/mL)
injections of 2 mg/kg NT4 for 21 or 30 days displayed 2 to 3-fold
increase in daily food intake (Fig. 3a and Supplemental Fig. S3a)
and 1.6 to 2.3-fold increase in cumulative food intake respectively
(Fig. 3b and Supplemental Fig. S3b). Food intake reverted to
normal levels within 10 days of dosing termination. Consequently,
such daily SC or IV administrations of NT4 resulted in a 16% (SC
for 21 days) or 33% (IV for 30 days) increase of body weight,
respectively (Fig. 3c and Supplemental Fig. S3c). These results
revealed a robust pro-obesity and orexigenic effect following
peripheral delivery of NT4 in the non-human primates. No
significant changes in water intake (Fig. 3d), menstrual cycle,
peripheral blood cell counts, insulin, C peptide, triglycerides, total
cholesterol, HDL, LDL, free fatty acids, or electrolytes were
detected in the Cynomolgus monkeys (Supplemental Figs. S4, S5,
S6, and data not shown). These results indicate that, in general,
peripheral administration of NT4 was well tolerated and that the
weight gain was not accompanied by hemodilution or fluid
retention.
To test whether TrkB activation alone is sufficient to induce
obesity and appetite, lean, adult female Cynomolgus monkeys
were treated twice a week with IV injections of 5 mg/kg of the
TrkB agonist antibody. These monkeys also exhibited 40%
increase in cumulative food intake (Fig. 3e) and 10% increase in
body weight (Fig. 3f) within 2 weeks. Thus activation of the TrkB
tyrosine kinase receptor by peripheral administration of a natural
agonist, NT4, or by a TrkB agonist antibody, leads to potent
orexigenic and pro-obesity effects in primates.
Peripheral NT4 Injections Increase Food Consumption,
Body Weight, Fat Mass and Circulating Leptin in Obese
Baboons
To determine the generality and effectiveness of peripheral
TrkB agonists as orexigenic signal in primates, adult obese female
baboons were injected IV with 2 mg/kg of NT4 daily for 25 days.
Despite being obese at baseline, all NT4-treated animals increased
their daily food intake by 2 to 3-fold (Fig. 4a) and consumed the
entire daily food allowance of 35 biscuits up to 18 days. When the
food allowance was raised to 45 biscuits per day (day 19 through
day 25), two of the animals still consumed the entire allowance
(Supplemental Fig. S7a). The cumulative food intake during the
period of NT4 treatment was increased by 2.5-fold (Supplemental
Fig. S7b). The hyperphagic behavior subsided within 7 days after
the last dose of NT4 (Fig. 4a). Daily infusion of NT4 also led to a
16% gain in body weight in these obese baboons, which took more
than 30 days to revert to baseline level following treatment
withdrawal (Fig. 4b). Consistent with the weight gain, these NT4
treated baboons exhibited significantly higher fasting serum leptin
levels (94336841 pg/mL, n=3) than those in the control group
(270761603 pg/mL, n=3) after 3 weeks of treatment (P,0.05,
Student’s t-test). No significant change in the fasting serum levels
of amylin, ghrelin, insulin, pancreatic peptide, PYY, IL-6 or TNF-
a were observed (data not shown).
Dual X-ray absorptiometry (DEXA) scan revealed a profound
effect of NT4 treatment on body composition (Fig. 4c and 4d).
NT4 treated baboons had gained 1.6560.31 kg (mean6SEM)
while vehicle treated baboons lost 1.3660.47 kg of total fat mass
(Fig. 4c, P=0.01, two-tailed Student’s t test with Welch
correction). There was no significant difference in lean body mass
(Fig. 4d, P=0.10) or in the bone mineral density (data not shown)
between the groups. Therefore, peripheral activation of TrkB
results in a potent orexigenic effect, leading to increase in body
weight and fat mass even in nonhuman primates with pre-existing
obesity.
Pro-Obesity Effects of Peripheral NT-4 Injections Is Not
Due to Receptor Desensitization
It was formally possible that chronic exposure to potent TrkB
agonists could have led to TrkB receptor downregulation and
hence a loss-of-function phenotype. We therefore examined the
effect of intermittent, twice a week IV dosing with 2 mg/kg NT4
Figure 2. Centrally, but not peripherally, delivered TrkB
agonists suppress food intake in Rhesus monkeys. a, Vehicle
infusion into normal adult Rhesus monkeys (baseline body weight 4–
7 kg) via an ICV catheter did not substantially change the food
consumption (n=2 males and 2 females per group). b, Dose dependent
and reversible decrease in food intake followed ICV infusion into normal
adult Rhesus monkeys of increasing doses of NT4 or BDNF (n=2 males
and 2 females per group). c , Daily SC injections of 2 mg/kg NT4 (n=1
male and 2 females per group) over 21 days in lean, adult Rhesus
monkeys (baseline body weight 3–6 kg) did not significantly alter the
level of daily food intake.
doi:10.1371/journal.pone.0001900.g002
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treated animals gradually gained up to 7–8%, while the vehicle
group lost 3–4% of body weight on average, resulting in a
significant difference between these groups (Fig. 4f). No significant
change in food intake, however, accompanied the weight gain
(Fig. 4e).
The similar pro-obesity effect following either daily or twice a
week dosing of NT4 (Figs. 4a–f), which in primates has an half-life
Figure 3. Peripheral application of TrkB agonists leads to gain in appetite, fat deposits and weight in lean Cynomolgus monkeys. a–
d, Daily treatment of non-obese, adult females, Cynomolgus (baseline body weight 3–5 kg) with 2 mg/kg/day NT4 IV (n=3 per group) for 30 days
led to a significant increase in daily food intake (a), cumulative food intake (b) and body weight (c) without significant change in water intake (d). e–
f, Lean, adult female Cynomolgus monkeys (n=3 per group) that were treated twice a week with IV injections of 5 mg/kg of a TrkB agonist antibody
exhibited a significant increase in cumulative food intake (e) and weight gain (f)
doi:10.1371/journal.pone.0001900.g003
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PLoS ONE | www.plosone.org 4 April 2008 | Volume 3 | Issue 4 | e1900Figure 4. Effects of TrkB agonists on appetite and weight in obese baboons. a–d, Daily IV infusion of 2 mg/kg of NT4 for 25 days into
obese baboons (baseline body weight 20–30 kg, n=3 per group) lead to a reversible increase in food intake (a) and body weight (b). Dual X-ray
absorptiometry (DEXA) scan revealed an increase in total fat (c), with no change in lean body mass (d). e–f, IV dosing twice a week with 2 mg/kg NT4
over a period of 6 weeks lead to weight gain (f) with no significant change in food intake (e) in obese baboons (n=3 per group). g, A schematic
model depicting the dual, anorexic and orexigenic axes of the TrkB signaling system.
doi:10.1371/journal.pone.0001900.g004
TrkB and Weight Control
PLoS ONE | www.plosone.org 5 April 2008 | Volume 3 | Issue 4 | e1900of less then 30 minutes (data not shown), is incompatible with the
hypothesis of TrkB receptor down regulation. Likewise, no
consistent changes in TrkB receptor levels in the baboon
peripheral white blood cells, that could have indicated receptor
down regulation, were detected following 24 daily IV treatments
with 2mg/kg NT4 (Supplemental Fig. S7c). Finally, consistent
with these observations in primates, there is no evidence of TrkB
tolerance, desensitization or resistance in any mouse models with
any dosages of TrkB agonists we have tested (Fig. 1). These
findings indicate that the pro-obesity effects of peripherally applied
NT4 are not mediated by receptor down-regulation and that
peripheral NT4 administration may directly reduce metabolic rate
independent of its effect on food intake in the nonhuman primates.
Discussion
The findings described here suggest the existence in the
primates of a novel, peripherally accessible, orexigenic and pro-
obesity TrkB axis that opposes the traditional, centrally located
anorexigenic TrkB axis (Fig. 4g). Both arms of the system utilize
the TrkB signaling pathway and the metabolic end result would be
determined by the relative strength of differentially localized TrkB
signals. To our knowledge, this represents the first example in
primates of diametrically opposite metabolic and behavioral
outcomes mediated by the same signaling pathway via spatial
compartmentalization. The anatomical sites of action for the
peripherally accessible, orexigenic TrkB signal are currently
unknown, but may include the enteric nervous system, the
pancreatic and gut neuro-endocrine system, the vagal nerve
and/or the circumventricular organs.
The default state of the TrkB system in the whole body appears
to be anorexigenic as indicated by the fact that rodents [2,3,5] or
humans [6,7] carrying a loss of function allele of BDNF or TrkB
locus exhibited early onset obesity and hyperphagia. However, the
anorexigenic TrkB stimulus, which is mediated by BDNF in the
VMH, is under dietary control and was shown to be suppressed
following fasting in mice [3]. Therefore, under a given
physiological state, either the central anorexigenic or the
peripheral orexigenic TrkB system could dominate the metabolic
outcome dependent on the relative levels of receptor activation
(Fig. 4g). The peripherally accessible, orexigenic TrkB axis is either
absent in rodents or had been quantitatively masked by the more
dominant, central anorexigenic TrkB axis, which in small animals
may be more accessible to peripherally applied TrkB receptor
agonists [13].
Interestingly, adult anorexia nervosa patients reportedly display
lower than normal serum levels of BDNF while obese adults
present higher than normal serum BDNF levels [14,15,16,17].
Until now these findings had been interpreted to be a failed
compensatory response of the central anorexigenic TrkB system
analogous to that observed with the leptin system [18,19]. Our
data now raise the distinct possibility that eating disorders such as
anorexia nervosa may be caused in part by the ‘‘sub-normal’’
levels of circulating BDNF and the resultant failure to activate the
peripherally accessible orexigenic TrkB axis. Conversely, obesity
may be due in part to the ‘‘supra-normal’’ levels of peripheral
BDNF which over-activate the orexigenic TrkB signaling.
Significant amounts of BDNF are present in the platelets [20]
and the pituitary gland [21], providing potential sources of TrkB
agonists for peripheral regulation of the orexigenic TrkB axis. If
true, selective activators of the peripherally accessible orexigenic
TrkB site would represent novel therapeutic agents for anorexia
and cachexia while selective inhibitors of this system may find
utility in the treatment for hyperphagia and obesity.
Methods
Additional details of materials and methods used are provided
in the Supplemental Methods S1.
Proteins
Recombinant human BDNF protein was purchased from
Peprotech (Rocky Hill, New Jersey). Recombinant human NT4
protein was purified and refolded from an E. coli culture
engineered to over-express NT4, using standard procedures (see
Supplemental Methods S1). TrkB agonist antibodies were
generated using the entire extracellular domain of human TrkB
protein as the immunogen in Balb/c mice to generate hybridomas
(see Supplemental Methods S1).
Animal studies
All animal experiments were conducted according to the
protocols approved by the IACUC of the respective institutions
(see Supplemental Methods S1). Details of various routes of
compound administration, measurement of food consumption and
body weight were described in Supplemental Methods S1.
Through out this paper, ‘‘Day 1’’ of a given study denotes the
day when the first dose of a therapeutic agent was given.
Statistics
All data and graphs were expressed in mean6SEM. Statistical
analyses were performed by using PRISM (GraphPad Software
Inc., San Diego, CA). Unless otherwise specified, all animal time
course studies were analyzed by two-way ANOVA followed by
Bonferroni post tests if and only if the overall P value is less than
0.05. The symbol * denotes P,0.05, ** P,0.01 and *** P,0.001
for pairwise comparisons by Student’s t-test, by Dunnett’s post test
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